Single Pass, Inc. published a retrospective multicenter study of the SinglePass biopsy closure device at Hoag Health System across 120 consecutive patients with 30-day follow-up showing 100% technical success and zero clinically significant bleeding events.
Public source
Publisher name
Public post
New in JVIR: a retrospective multicenter study of the SinglePass biopsy closure device at Hoag Health System. Across 120 consecutive patients with 30-day follow-up: • 10…
Company
Single Pass, Inc.
Stop Bleeding in its Tract with the Single Pass biopsy closure device.
- Industry
- Medical Equipment Manufacturing
- Location
- Lake Forest, US
- Company size
- 11–50 employees
About Single Pass, Inc.
The Kronos Electrocautery device efficiently seals biopsy channels, enhancing safety for high-risk patients and enabling the use of larger needles for more substantial tissue samples in few \er passes. Its usage may reduce procedure costs by eliminating the need for certain medications, hemostatic agents, and post-procedure observation.
See moreLatest activity
Latest activity from Single Pass, Inc.
5 signals
Presence & Recognition
Single Pass, Inc. sponsored the Society of Interventional Radiology Industry Insights Webinar on Sept 23, 2026, covering the clinical and economic impact of complications following CT-guided percutaneous lung biopsy and sealing the biopsy tract with thermal cautery.
Presence & Recognition
Single Pass, Inc. is hosting a session on lung biopsies featuring Dr. Fereidoun Abtin, Dr. Joseph Mammarappallil, and Dr. Alexander Misono, MD, MBA, RPVI.
Presence & Recognition
Single Pass, Inc. is attending the CIRSE conference to discuss New Strategies in Biopsy Closure.
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
Argon Medical Devices, Inc.
Argon Medical Devices, Inc. published outcomes from 110 patients treated across interventional radiology and vascular care settings using the CLEANER Vac Thrombectomy System.
Research & Knowledge
iVascular
iVascular presented the 1-year outcomes of the iliCo study at CIRSE 2026, showing strong results for iCover in aortoiliac occlusive disease with 96.7% fTLR and patient clinical improvement of 90.4%
Research & Knowledge
Solaris Endovascular
Solaris Endovascular announced 92.7% target lesion primary patency at six months with investigational Solaris DE in the DEScover Phase II study presented at CIRSE 2026.
Research & Knowledge
Endologix LLC
Endologix LLC published a retrospective study of the Ovation stent graft with Adaptive Sealing Technology demonstrating long-term outcomes of durable abdominal aortic aneurysm exclusion through extended follow-up with a mean of 83 months.
Research & Knowledge
Cagent Vascular